Holocene Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Holocene Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-690,000	Closed	-$40.6M	–	681
2020 Q2	$40.6M	Buy	+690,000	New	+$41.3M	0.36%	87

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Holocene Advisors's BMY Position: Q1 2025 in Review

Holocene Advisors sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 147,965 shares — an estimated $8.37M sold.

Holocene Advisors first reported a position in BMY in Q2 2019 and held it in 2 quarters. The position peaked at $9.86M in Q2 2019. 2,477 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

Holocene Advisors reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
Holocene Advisors sold 147,965 Bristol-Myers Squibb shares in Q1 2025, an estimated $8.37M.
Holocene Advisors first reported a position in Bristol-Myers Squibb in Q2 2019 and held it in 2 quarters.
Holocene Advisors's Bristol-Myers Squibb position peaked at $9.86M in Q2 2019.
2,477 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on Holocene Advisors's 13F filing for Q1 2025, filed 15 May 2025.